We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A newly published Q&A document from the FDA and the European Medicines Agency (EMA) outlines the similarities — and differences — in the two agencies’ requirements for manufacturing breakthrough products. Read More
The FDA has smacked Fresenius Kabi with a warning letter for selling adulterated devices that fail to conform to current good manufacturing practice (cGMP) requirements, following an inspection of the devicemaker’s Waltham, Mass., facility from June 26 to Aug. 2. Read More
A recently approved position paper from the European Association of Medical Devices Notified Bodies — referred to as Team-NB — addresses the question “What should ‘lifetime’ mean in guidelines when referring to the lifespan of medical devices?” Read More
In this edition of Quick Notes, we look at FDA breakthrough designation for a pulsed ablation system for treatment of atrial fibrillation, an implant to treat glaucoma and ocular hypertension, a label expansion for a game-based digital therapeutic device for adolescents with ADHD, and an antigen test to detect the presence of a cancer-causing bacteria. Read More
In observance of the holiday season, FDAnews will not be published Friday, Dec. 22, or Monday, Dec. 25. The next issue will be published Tuesday, Dec. 26. Happy Holidays! Read More
In a final guidance issued this week, the FDA outlines recommendations for continued development of monoclonal antibody products targeting SARS-CoV-2 to meet emergency needs. Read More
Olympus Corporation of the America’s recall of 17,691 bronchofiberscopes and bronchovideoscopes due to burn and fire hazards has been identified as a Class I recall. Read More
Upcoming events in the coming weeks and months include two FDA advisory committee meetings; and MAGI 2024: The Clinical Research Conference in New Orleans, and an FDAnews sponsored webinar on manufacturing medical devices with AI-integrated QMS. Read More
A recent study raises questions about the safety of Sage Therapeutics’ Zurzuvae (zuranolone) for postpartum depression, charging that the drug exerts risks similar to those seen with benzodiazepines and that the clinical trials supporting its approval were inappropriately conducted. Read More
Apple is pausing U.S. sales of its new Series 9 and Ultra 2 Apple watches due to a dispute with Masimo, a monitoring technologies medtech company, that alleges certain Apple watches violate its heart rate and blood oxygen monitor patents. Read More